Program
Hyaluronoglucosaminidase
Also written as “HYQVIA”, “HyQvia” and “hyaluronidase”.
Its studies are mostly in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Primary Immunodeficiency Diseases · Hypersensitivity, led by 4 companies.
Drug pageHyaluronoglucosaminidase: every studyAll 32 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 60 open or running | phase 4since Apr 12, 2017 | Sep 11, 2015 | none ahead |
| Amphastar Pharmaceuticals | 10 open or running | phase 2since Sep 13, 2012 | Sep 13, 2012 | none ahead |
| Baxter Healthcareits history only | 10 open or running | phase 1since Jun 26, 2007 | Jun 26, 2007 | none ahead |
| Shanghai Bao Pharmaceuticalsits history only | 10 open or running | phase 3since Sep 12, 2024 | Sep 12, 2024 | none ahead |
Also a collaborator on its studies: Takeda Development Center Americas, Baxalta Innovations GmbH, now part of Shire and Halozyme Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Amphastar Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 13, 2012First study: phase 2 study in HypersensitivityFirst studyNCT01689363 · 253 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Amphastar Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01689363Hypersensitivity · United States | 2 | Completed | Nov 2012 | 253 |
How it is read
Names in the registry
- “HYQVIA”, 10 entries
- “HyQvia”, 1 entry
- “hyaluronidase”, 1 entry
- “Hyaluronidase”, 1 entry
- “SC HYLENEX and Ceftriaxone”, 1 entry
Conditions, from the studies’ own filings
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 2 studies
- Primary Immunodeficiency Diseases, 2 studies
- Hypersensitivity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.